Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.

Share

Program Content

Activities

HER2+ MBC Novel Therapies
Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer
Congratulations: You achieved a completion on 04/09/2022

Activities

T-DXd: ILD Management
How I Manage Interstitial Lung Disease Associated With Trastuzumab Deruxtecan in My Patients With HER2-Positive MBC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2020

Expires: September 09, 2021

FAQ: HER2+ MBC
Frequently Asked Questions in HER2-Positive Metastatic Breast Cancer Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 11, 2020

Expires: September 10, 2021

Activities

Novel Anti-HER2 MAb/Cases
Novel Anti-HER2– Monoclonal Antibody and Case Discussions on Novel HER2-Directed Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2020

Expires: May 28, 2021

Novel Anti-HER2 ADCs
Novel Anti-HER2–Directed Antibody–Drug Conjugates
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2020

Expires: May 28, 2021

Novel Anti-HER2 TKIs
Novel Anti-HER2–Targeted Tyrosine Kinase Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2020

Expires: May 28, 2021

<i>EP</i>: HER2-Positive MBC
ExpressPoints: Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2020

Expires: May 28, 2021

Activities

HER2+ MBC Case Discussion
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: September 21, 2020

Expires: September 20, 2021

Faculty

cover img faculity

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Leon Bérard
Lyon, France

cover img faculity

Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.